Marta Raimondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marta Raimondo has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Mortaruolo
Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy
2 shared publications - Claudia Giordano
Department of Clinical Medicine and Surgery, Hematology Unit Federico II University Medical School Naples Italy
2 shared publications - Fabio Trastulli
Division of Hematology, AO “A. Cardarelli’’ Hospital, Naples, Italy
2 shared publications - Fabrizio Pane
Department of Clinical Medicine and Surgery, Hematology Unit Federico II University Medical School Naples Italy
2 shared publications - Marco Picardi
Department of Clinical Medicine and Surgery, Hematology Unit Federico II University Medical School Naples Italy
2 shared publications - Novella Pugliese
Department of Clinical Medicine and Surgery, Hematology Unit Federico II University Medical School Naples Italy
2 shared publications
Latest Publications
- Open Access
- 14 May 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (9) , 1546-1552
Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
We evaluated the impact on progression-free survival (PFS) of achieving a deep metabolic response at 2-deoxy-2[18F] fluoro-d-glucose positron emission tomography (FDG-PET) in patients with refractory or relapsed (R/R) classic Hodgkin lymphoma (cHL) following a new salvage regimen named Bv+Bs (brentuximab vedotin + bendamustine supercharge), from 2013 to 2017. In this real-life study, 20 consecutive patients (aged 2 per day, for a total of 4 courses. A robust primary prophylaxis approach, including premedication, antimicrobials, stimulating factors, and cytomegalovirus monitoring, was systematically performed. The 20 patients (all evaluable) underwent 4 courses of Bv+Bs with a median dose intensity of 100% for both Bv and Bs. Ten patients (50%) experienced grade ≥3 treatment-related adverse events, without requiring hospitalization. At post-Bv+Bs reevaluation, 80% of patients had deep metabolic responses with Deauville 5-point scale scores ≤2. Thereafter, 14 patients (70%) received autologous hematopoietic stem cell transplantation (HSCT; peripheral blood stem cells previously harvested in 12 cases), and 4 patients (10%) received allogeneic HSCT. At a median follow-up of 27 months from Bv+Bs regimen initiation, the 2-year PFS of the entire population was 93.7% (95% confidence interval, 62.7% to 99.6%). Our data suggest that Bv+Bs regimen-driven strategy may be a promising salvage option to improve long-term control of high-risk Hodgkin lymphoma. Key Points FDG-PET–negative status achieved with salvage therapy is the most important determinant of favorable outcome after HSCT, for patients with R/R cHL. Our modified Bv+Bs salvage regimen led to deep metabolic responses in the majority of patients, establishing a bridge to transplant. Visual Abstract
- 14 May 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (9) , 1546-1552
Open AccessBrentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
We evaluated the impact on progression-free survival (PFS) of achieving a deep metabolic response at 2-deoxy-2[18F] fluoro-d-glucose positron emission tomography (FDG-PET) in patients with refractory or relapsed (R/R) classic Hodgkin lymphoma (cHL) following a new salvage regimen named Bv+Bs (brentuximab vedotin + bendamustine supercharge), from 2013 to 2017. In this real-life study, 20 consecutive patients (aged 2 per day, for a total of 4 courses. A robust primary prophylaxis approach, including premedication, antimicrobials, stimulating factors, and cytomegalovirus monitoring, was systematically performed. The 20 patients (all evaluable) underwent 4 courses of Bv+Bs with a median dose intensity of 100% for both Bv and Bs. Ten patients (50%) experienced grade ≥3 treatment-related adverse events, without requiring hospitalization. At post-Bv+Bs reevaluation, 80% of patients had deep metabolic responses with Deauville 5-point scale scores ≤2. Thereafter, 14 patients (70%) received autologous hematopoietic stem cell transplantation (HSCT; peripheral blood stem cells previously harvested in 12 cases), and 4 patients (10%) received allogeneic HSCT. At a median follow-up of 27 months from Bv+Bs regimen initiation, the 2-year PFS of the entire population was 93.7% (95% confidence interval, 62.7% to 99.6%). Our data suggest that Bv+Bs regimen-driven strategy may be a promising salvage option to improve long-term control of high-risk Hodgkin lymphoma. Key Points FDG-PET–negative status achieved with salvage therapy is the most important determinant of favorable outcome after HSCT, for patients with R/R cHL. Our modified Bv+Bs salvage regimen led to deep metabolic responses in the majority of patients, establishing a bridge to transplant. Visual Abstract
- 31 January 2019
- Published by American Society of Hematology in Blood
- Vol. 133 (5) , 498-501
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL
- 31 January 2019
- Published by American Society of Hematology in Blood
- Vol. 133 (5) , 498-501
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL